wegovy semaglutide news - Search News

Novo Nordisk, Wegovy

Barron's on MSN · 17h

Novo’s Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next.

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions. Approval in the U.S.–Novo’s biggest market for obesity drugs–by the Food and Drug Administration could be next.

Benzinga.com · 19h

European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.

Novo Nordisk's Wegovy Recommended For Label Update To Reflect Heart Failure Benefits

The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise function in people with obesity-related heart failure with preserved ejection fraction (HFpEF).

The Wall Street Journal on MSN · 1d

Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure

Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.

GlobalData on MSN20h

EMA CHMP recommends label update to Novo Nordisk’s Wegovy

Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) ...

Compounded semaglutide is an ill-defined public health crisis

Grappling with obesity and the metabolic diseases cascading from it, they are now among the plurality of Americans who have ...

1d

Hims & Hers offers compounded Wegovy for $99 a month to select professions

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

11d

Wegovy, Ozempic may someday be available as monthly injection

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...

Semaglutide Bests Liraglutide in Long-Term Weight Loss

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

Everyday Health7d

Wegovy May Reduce the Risk of Death From COVID-19, Study Suggests

A new study found that people taking Wegovy during the pandemic were 33 percent less likely to die of COVID-19.

What Expanded CVD Medicare Coverage May Mean for Novo Nordisk’s Wegovy

A recent study estimated that Wegovy’s label expansion beyond obesity could push Medicare spending to $145 billion annually, ...

Semaglutide Reduces MACE, Death in Participants With CVD, Overweight/Obesity, and Impaired Kidney Function

A SELECT trial subanalysis showed that semaglutide works as well in people with CVD, overweight/obesity, and impaired kidney ...

healthday on MSN11d

Wegovy, Ozempic May Someday Be Given as Once-Monthly Injection

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of ...

Is Wegovy really a gamechanger for heart health? A consultant cardiologist gives his verdict

The weight-loss jab Wegovy has been hailed as an “absolute game-changer” after a new study showed that it relieved symptoms ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results